Viridian Therapeutics (VRDN) Financials: Revenue & Earnings
VRDN$23.91-0.18 -0.75%
$2.71B
Market Cap
-6.61
P/E
17.02
Forward P/E
—
Score
Viridian Therapeutics (VRDN) Financials: Revenue & Earnings
VRDN price $23.91 -0.18 -0.75%
- Ticker
- VRDN
- Price
- $23.91
- Change
- -0.18 -0.75%
- Market cap ?
- $2.71B
- P/E ?
- -6.61
- Forward P/E ?
- 17.02
- Dividend yield ?
- 0.00%
- Beta ?
- 0.96
- Sector
- Healthcare
- Industry
- Biotechnology
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 3337000 | 4003000 | 8386000 | 4461000 | 1050000 | 2963000 | 1772000 | 314000 | 302000 | 70849000 |
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation…
Fair value
VRDN fair value $30.83. Price $23.91. Price is 22% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 14.87M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 9.60% (beta 1.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 113.29M. Net debt -161.69M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -1.02 | — | 4.72M |
| 2026-08-06 | -1.05 | -1.03 | 284.00K | 56.36K |
| 2026-05-05 | -0.90 | -1.06 | 141.00K | 36.08K |
| 2026-02-26 | -1.08 | -0.90 | 132.00K | 18.38M |
| 2025-11-05 | -0.34 | -0.82 | 70.57M | 15.75M |
| 2025-08-06 | -1.00 | -1.00 | 75.00K | — |
| 2025-05-06 | -0.87 | -0.95 | 72.00K | 44.08K |
| 2025-02-27 | -0.81 | -1.05 | 72.00K | 50.00K |
| 2024-11-12 | -1.15 | -1.06 | 86.00K | 50.00K |
| 2024-08-08 | -1.02 | -0.89 | 72.00K | 80.00K |
| 2024-05-08 | -0.79 | -1.10 | 72.00K | 70.00K |
| 2024-02-27 | -1.35 | -1.00 | 72.00K | 154.18K |
| 2023-11-13 | -1.09 | -1.27 | 72.00K | 160.00K |
| 2023-08-08 | -1.27 | -1.29 | 72.00K | 100.00K |
| 2023-05-09 | -1.61 | -1.02 | 98.00K | 100.00K |
| 2023-03-08 | -1.13 | -0.73 | 105.00K | 510.00K |
| 2022-11-14 | -0.86 | -1.02 | 1.20M | 303.33K |
| 2022-08-15 | -1.06 | -0.90 | 256.00K | 270.33K |
| 2022-05-12 | -0.98 | -1.08 | 216.00K | 253.50K |
| 2022-03-10 | -1.32 | -0.85 | 214.00K | 342.80K |
| 2021-11-04 | -1.25 | -1.47 | 208.00K | 570.00K |
| 2021-08-11 | -2.21 | -1.52 | 1.09M | 762.88K |
| 2021-05-06 | -2.91 | -0.76 | 1.45M | 2.39M |
| 2021-03-25 | -5.31 | -1.27 | 54.00K | — |
| 2020-11-10 | -1.50 | -1.99 | — | — |
| 2020-08-05 | -1.80 | -2.47 | 168.00K | — |
| 2020-05-07 | -2.70 | -2.88 | 828.00K | — |
| 2020-03-11 | -4.65 | -3.78 | 880.00K | — |
| 2019-11-07 | -5.40 | -4.44 | 695.00K | — |
| 2019-08-07 | -4.35 | -5.59 | 2.51M | — |
| 2019-05-08 | -5.70 | -5.16 | 372.00K | — |
| 2019-03-13 | -4.95 | -4.62 | 476.00K | — |
| 2018-11-07 | -4.35 | -4.76 | 944.00K | — |
| 2018-08-07 | -4.35 | -4.35 | 2.18M | — |
| 2018-05-09 | -2.70 | -3.66 | 4.78M | — |
| 2018-03-14 | -4.35 | -4.76 | 1.19M | — |
| 2017-11-08 | -4.05 | -5.90 | 1.63M | — |
| 2017-08-11 | -5.10 | -7.05 | 718.00K | — |
| 2017-05-10 | -9.00 | -3.60 | 462.00K | — |
| 2017-03-24 | -7.23 | — | 756.00K | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | Sell | 10.00K | $14.41 | 144.10K |
| 2026-08-19 | Tousignant Jennifer | Buy | 10.00K | $14.41 | 144.10K |
| 2026-08-19 | Tousignant Jennifer | Sell | 10.00K | $24.50 | 245.00K |
| 2026-08-14 | Tripuraneni Radhika | Buy | 40.00K | $13.21 | 528.40K |
| 2026-08-14 | Tripuraneni Radhika | Sell | 40.00K | $13.21 | 528.40K |
| 2026-07-01 | CAIN CHRISTOPHER W. | Buy | 32.34K | $18.48 | 597.66K |
| 2026-07-01 | Ajer Jeffrey Robert | Buy | 32.34K | $18.48 | 597.66K |
| 2026-07-01 | Moses Jennifer K. | Buy | 32.34K | $18.48 | 597.66K |
| 2026-07-01 | Gheuens Sarah | Buy | 32.34K | $18.48 | 597.66K |
| 2026-07-01 | Kiselak Tomas | Buy | 32.34K | $18.48 | 597.66K |
| 2026-07-01 | Morris Arlene | Buy | 32.34K | $18.48 | 597.66K |
| 2026-05-11 | Fairmount Funds Management LLC | Buy | 1.18M | $17.00 | 20.00M |
| 2026-03-03 | Harmon Seth | Sell | 2.03K | $30.19 | 61.32K |
| 2026-03-03 | Beetham Thomas W. | Sell | 3.05K | $30.19 | 92.02K |
| 2026-03-03 | Tousignant Jennifer | Sell | 1.68K | $30.19 | 50.57K |
| 2026-03-03 | Mahoney Stephen F. | Sell | 7.41K | $30.19 | 223.65K |
| 2026-03-03 | Tousignant Jennifer | Sell | 5.17K | — | — |
| 2026-03-03 | Tousignant Jennifer | Buy | 5.17K | — | — |
| 2026-03-03 | Tousignant Jennifer | Sell | 1.72K | $29.32 | 50.55K |
| 2026-03-03 | Harmon Seth | Sell | 6.27K | — | — |
| 2026-03-03 | Harmon Seth | Buy | 6.27K | — | — |
| 2026-03-03 | Harmon Seth | Sell | 2.09K | $29.32 | 61.31K |
| 2026-03-03 | Beetham Thomas W. | Sell | 9.41K | — | — |
| 2026-03-03 | Beetham Thomas W. | Buy | 9.41K | — | — |
| 2026-03-03 | Beetham Thomas W. | Sell | 3.14K | $29.32 | 92.01K |
| 2026-03-03 | Mahoney Stephen F. | Sell | 18.36K | — | — |
| 2026-03-03 | Mahoney Stephen F. | Buy | 18.36K | — | — |
| 2026-03-03 | Mahoney Stephen F. | Sell | 7.63K | $29.32 | 223.62K |
| 2026-03-02 | Tousignant Jennifer | Buy | 119.30K | $30.25 | 3.61M |
| 2026-03-02 | Tousignant Jennifer | Buy | 23.85K | — | — |
| 2026-03-02 | Harmon Seth | Buy | 102.85K | $30.25 | 3.11M |
| 2026-03-02 | Harmon Seth | Buy | 20.55K | — | — |
| 2026-03-02 | Beetham Thomas W. | Buy | 176.55K | $30.25 | 5.34M |
| 2026-03-02 | Beetham Thomas W. | Buy | 35.30K | — | — |
| 2026-03-02 | Mahoney Stephen F. | Buy | 559.60K | $30.25 | 16.93M |
| 2026-03-02 | Mahoney Stephen F. | Buy | 111.90K | — | — |
| 2026-03-02 | Tripuraneni Radhika | Buy | 95.80K | $30.25 | 2.90M |
| 2026-03-02 | Tripuraneni Radhika | Buy | 19.15K | — | — |
| 2025-12-31 | Tousignant Jennifer | Sell | 2.27K | $31.16 | 70.80K |
| 2025-10-23 | Fairmount Funds Management LLC | Buy | 454.55K | $22.00 | 10.00M |
| 2025-07-01 | CAIN CHRISTOPHER W. | Buy | 21.00K | $14.47 | 303.87K |
| 2025-07-01 | Kiselak Tomas | Buy | 21.00K | $14.47 | 303.87K |
| 2025-07-01 | Morris Arlene | Buy | 21.00K | $14.47 | 303.87K |
| 2025-07-01 | Ajer Jeffrey Robert | Buy | 21.00K | $14.47 | 303.87K |
| 2025-07-01 | Gheuens Sarah | Buy | 21.00K | $14.47 | 303.87K |
| 2025-07-01 | Moses Jennifer K. | Buy | 21.00K | $14.47 | 303.87K |
| 2025-06-10 | Fairmount Funds Management LLC | Buy | 12.50K | $12.31 | 153.88K |
| 2025-06-10 | Fairmount Funds Management LLC | Sell | 12.50K | $12.31 | 153.88K |
| 2025-06-09 | Fairmount Funds Management LLC | Buy | 1.60K | $7.80 | 12.48K |
| 2025-06-09 | Fairmount Funds Management LLC | Sell | 1.60K | $7.80 | 12.48K |
| 2025-04-07 | Ajer Jeffrey Robert | Buy | 42.00K | $11.78 | 494.76K |
| 2025-04-07 | Ajer Jeffrey Robert | Other | 0 | — | — |
| 2025-03-10 | Tripuraneni Radhika | Buy | 310.70K | $15.58 | 4.84M |
| 2025-03-10 | Tripuraneni Radhika | Other | 40.00K | $13.21 | 528.40K |
| 2025-03-10 | CAIN CHRISTOPHER W. | Buy | 42.00K | $15.58 | 654.36K |
| 2025-03-10 | CAIN CHRISTOPHER W. | Other | 0 | — | — |
| 2025-03-03 | Harmon Seth | Other | 0 | — | — |
| 2025-03-03 | Tousignant Jennifer | Other | 0 | — | — |
| 2025-03-03 | Tousignant Jennifer | Buy | 124.07K | $14.41 | 1.79M |
| 2025-03-03 | Tousignant Jennifer | Buy | 20.68K | — | — |
| 2025-03-03 | Mahoney Stephen F. | Buy | 440.56K | $14.41 | 6.35M |
| 2025-03-03 | Mahoney Stephen F. | Buy | 73.43K | — | — |
| 2025-03-03 | Beetham Thomas W. | Buy | 225.81K | $14.41 | 3.25M |
| 2025-03-03 | Beetham Thomas W. | Buy | 37.64K | — | — |
| 2025-03-03 | Harmon Seth | Buy | 150.41K | $14.41 | 2.17M |
| 2025-03-03 | Harmon Seth | Buy | 25.07K | — | — |
| 2024-09-27 | Beetham Thomas W. | Buy | 5.00K | $23.41 | 117.05K |
| 2024-09-27 | Mahoney Stephen F. | Buy | 21.40K | $23.33 | 499.26K |
| 2024-09-13 | Fairmount Funds Management LLC | Buy | 1.60M | $18.75 | 30.00M |
| 2024-06-26 | Gheuens Sarah | Buy | 21.00K | $12.31 | 258.51K |
| 2024-06-26 | Morris Arlene | Buy | 21.00K | $12.31 | 258.51K |
| 2024-06-26 | Moses Jennifer K. | Buy | 21.00K | $12.31 | 258.51K |
| 2024-06-26 | Harwin Peter Evan | Buy | 21.00K | $12.31 | 258.51K |
| 2024-06-26 | Kiselak Tomas | Buy | 21.00K | $12.31 | 258.51K |
| 2024-03-28 | Fairmount Funds Management LLC | Buy | 5.86K | — | — |
| 2024-03-28 | Fairmount Funds Management LLC | Buy | 22.00K | — | — |
| 2024-03-28 | Fairmount Funds Management LLC | Sell | 5.86K | — | — |
| 2024-03-28 | Fairmount Funds Management LLC | Sell | 22.00K | — | — |
| 2024-02-12 | Tousignant Jennifer | Other | 0 | — | — |
| 2024-02-12 | Tousignant Jennifer | Buy | 290.00K | $19.68 | 5.71M |
| 2024-02-05 | Ciulla Thomas | Buy | 50.00K | $18.70 | 935.00K |
| 2024-01-22 | Fairmount Funds Management LLC | Buy | 476.19K | $21.00 | 10.00M |
| 2024-01-03 | Ciulla Thomas | Sell | 0 | — | — |
| 2024-01-03 | Ciulla Thomas | Sell | 250.00K | $33.06 | 8.27M |
| 2024-01-03 | Ciulla Thomas | Sell | 270.00K | $13.76 | 3.72M |
| 2024-01-03 | Ciulla Thomas | Sell | 50.00K | $28.22 | 1.41M |
| 2023-11-10 | Harmon Seth | Buy | 270.00K | $13.76 | 3.72M |
| 2023-10-30 | Fairmount Funds Management LLC | Buy | 48.46K | — | — |
| 2023-10-30 | Beetham Thomas W. | Other | 0 | — | — |
| 2023-10-30 | Beetham Thomas W. | Buy | 474.40K | $13.02 | 6.18M |
| 2023-10-30 | Mahoney Stephen F. | Buy | 1.26M | $13.02 | 16.40M |
| 2023-10-30 | Mahoney Stephen F. | Other | 0 | — | — |
| 2023-09-21 | Gheuens Sarah | Buy | 40.00K | $15.74 | 629.60K |
| 2023-09-21 | Gheuens Sarah | Other | 0 | — | — |
| 2023-09-12 | Harmon Seth | Sell | 175.00K | $24.50 | 4.29M |
| 2023-06-16 | Meisner Lara | Sell | 28 | $23.03 | 645 |
| 2023-06-16 | Meisner Lara | Buy | 27 | $23.03 | 622 |
| 2023-06-16 | Meisner Lara | Sell | 27 | $28.35 | 765 |
| 2023-06-15 | Meisner Lara | Sell | 2.27K | $23.03 | 52.26K |
| 2023-06-15 | Meisner Lara | Buy | 2.27K | $23.03 | 52.26K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 227, holders -3 vs prior quarter. Ownership 126.86%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 16.60M | 1.23M | +7.97% | 305.03M |
| BLACKROCK, INC. | 8.55M | 720.01K | +9.19% | 157.09M |
| BELLEVUE GROUP AG | 6.73M | 5.76K | +0.09% | 123.67M |
| PARADIGM BIOCAPITAL ADVISORS LP | 6.72M | 3.57M | +113.53% | 123.52M |
| KYNAM CAPITAL MANAGEMENT, LP | 6.45M | 4.11M | +175.61% | 118.56M |
| STATE STREET CORP | 6.12M | 1.45M | +31.07% | 112.52M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.75M | 2.54M | +79.30% | 105.60M |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 5.09M | 1.18M | +30.05% | 93.52M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.58M | 409.66K | +9.83% | 84.08M |
| DEEP TRACK CAPITAL, LP | 3.59M | 2.20M | +157.74% | 66.00M |
| VENROCK ADVISER, LLC | 3.26M | -624.79K | -16.09% | 59.85M |
| WELLINGTON MANAGEMENT GROUP LLP | 3.13M | 49.81K | +1.62% | 57.47M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.75M | 1.11M | +67.70% | 50.57M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.50M | 168.66K | +7.23% | 45.97M |
| AVORO CAPITAL ADVISORS LLC | 2.50M | 1.00M | +66.67% | 45.92M |
| BAKER BROS. ADVISORS LP | 2.38M | 411.35K | +20.86% | 43.78M |
| POINT72 ASSET MANAGEMENT, L.P. | 2.34M | 2.02M | +625.82% | 43.04M |
| CALIGAN PARTNERS LP | 2.19M | 2.19M | New | 40.30M |
| NOVO HOLDINGS A/S | 2.13M | 135.00K | +6.75% | 39.22M |
| TANG CAPITAL MANAGEMENT LLC | 1.79M | 0 | 0.00% | 32.93M |
| FISHER ASSET MANAGEMENT, LLC | 1.75M | -17.45K | -0.99% | 32.16M |
| CANDRIAM S.C.A. | 1.71M | 995.96K | +139.93% | 31.34M |
| GOLDMAN SACHS GROUP INC | 1.69M | 99.36K | +6.24% | 31.07M |
| FIRST TURN MANAGEMENT, LLC | 1.67M | 758.66K | +83.25% | 30.68M |
| DIMENSIONAL FUND ADVISORS LP | 1.61M | 1.08M | +204.20% | 29.61M |
Earnings and financials
Viridian Therapeutics, Inc. (VRDN) trades at $23.91, with a market cap of $2.71B and a trailing P/E of -6.61. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 3337000 | 4003000 | 8386000 | 4461000 | 1050000 | 2963000 | 1772000 | 314000 | 302000 | 70849000 |
Insights · Dividends · Forecast · Financials · Learn